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did not show signiﬁcant trend between responders and non
responders. Thus, sCD25 and TNFb can be potentially used as
biomarkers to predict response of cGvHD to ECP. Studies with
larger number of patients on ECP will be required to conﬁrm
these ﬁndings.429
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The cGVHD Symptom Bother Scale, known as the Lee cGVHD
scale, is a patient reported questionnaire developed and
validated in English to measure symptoms and functional
losses in patients (pts.) with cGVHD. The Lee cGVHD scale
includes 30 questions with 7 subscales containing 2 to 7
items representing domains of skin, mouth, respiratory
system, gastrointestinal system, energy and psychological
status. The Lee cGVHD scale was translated into Portuguese
and validated according to the American Association of
Orthopedic Surgeons Outcome Committee guideline. 47 adult
pts with cGVHD diagnosed according to the 2005 NIH
consensus criteria were studied by the Brazil-Seattle cGVHD
Consortium between 2011 to 2012 at 5 centers. Median age
was 48 years (23-69) and 29 (61.7%) were male. All pts.
completed the Brazilian version of the Lee cGVHD ques-
tionnaire, the Medical Outcomes Study Short Form 36 (SF-
36) and the Functional Assessment of Chronic Illness Therapy
with Bone Marrow Transplant subscale (FACT-BMT). Overall
cGVHD severity was also assessed by pt. (0-3 scale) and by
physician (0-10 scale). Reliability was assessed using Cron-
bach's alpha and intraclass correlation coefﬁcients. Spear-
man's correlation coefﬁcient was used to measure constructOther Evaluations
Lee chronic GVHD Scale (0-100)y
Energy Skin Nutrition
SF-36
Physical Summary -0.49* -0.41* -0.43*
Emotional Summary -0.54* -0.32* -0.34*
FACT-BMT Summary 0.48* 0.40* 0.34*
GVHD severity rated by:
Physician 0.17 0.27 0.45*
Patient -0.04 0.15 0.25
* Correlation is signiﬁcant at the 0.05 level (2-tailed)
y Numbers represent Spearman’s correlation coefﬁcient: Very Low: 0.0< r  0.2validity. Results showed the reliability of the Lee cGVHD scale
was satisfactory (Cronbach's alpha 0.62-0.83). Correlation
coefﬁcients were moderate between similar domains of the
Lee cGVHD scale, SF-36, FACT-BMT and overall cGVHD
severity as rated by the physician but, correlation was low
between Lee cGVHD scale and overall cGVHD severity
assessed by patient (Table). The Brazilian Portuguese version
of the Lee cGVHD scale is reliable and easy to apply but
a larger cohort is needed to validate the instrument in this
population.430
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Background: Allogeneic hematopoietic stem cell trans-
plantation is a curative treatment for a number of hemato-
logical malignancies. Graft-versus-host disease (GVHD)
remains a leading cause of morbidity and mortality. Rabbit
anti-thymocyte globulin (ATG) is used to reduce the inci-
dence of GVHD. However, dosing regimens and schedules
vary.
Methods:We reviewed the medical records of 88 patients at
our institutionwho received ATG at either 4.5 or 6.0mg/kg, in
combination with tacrolimus and mycophenolate, prior to
allogeneic stem cell transplantation between 2009 and 2011.
ATG was administered over 3 days, ﬁnishing on day 0. We
retrospectively evaluated the prophylactic effect of each ATG
dosing regimen by measuring the incidence of severe (grade
III-IV) acute GVHD and acute GVHD-associated mortality. We
also measured relapse rate, overall survival (OS) and
progression-free survival (PFS) for both groups.
Results: A total of 52 patients who received ATG at 4.5mg/kg
(ATG1) were comparedwith 36 patients who received ATG at
6.0mg/kg (ATG2). The degree of HLA-mismatching was
greater in ATG2 (39.1% mismatched unrelated donors) as
compared to ATG1 (10% mismatched unrelated donors)
(P¼0.019) among 53 recipients from unrelated donors.
Median follow up for ATG1was 362 days, as compared to 512
days for ATG2. The cumulative incidence of grade III-IV acute
GVHD at day 100 was 13.9% and 6.5% in the ATG1 and ATG2
groups, respectively (P¼0.256). Speciﬁcally, 6 patients in
ATG1 developed grade IV GHVD, as compared to 0 patients in
ATG2. Acute GVHD-associated mortality was 7.7% and 0% in
ATG1 and ATG2, respectively (P¼0.141). All GVHD-associated
deaths occurred in patients with grade IV GVHD. The relapse
rates were comparable between ATG1 and ATG2 for bothLung Psych Eye Mouth Summary
-0.32* -0.51* -0.26 -0.35* -0.66*
-0.31* -0.70* -0.25 -0.27 -0.63*
0.18 0.49* 0.01 0.42* 0.48*
0.11 0.20 0.44* 0.27 0.51*
-0.07 0.06 27 0.21 0.25
, Low. 0.2 < r  0.4, Moderate 0.4 < r  0.6, High 0.6 < r
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conditioning (13% vs. 9%, P¼1.000). PFS at 1 year was slightly
higher for ATG1 (52.8% vs. 45.5%,P ¼ .955), while OS at 1 year
was not different between the two groups (53.7% vs 55.4%,P
¼ .779).
Conclusion: A small decrease in the prophylactic ATG dose
(1.5mg/kg) had a signiﬁcant clinical impact. An increased
incidence of severe lethal acute GVHD was observed with
4.5mg/kg dosing despite a greater degree of HLA-matching.
The 6.0mg/kg dosing prevented grade IV acute GVHD and
associated mortality. Further research is warranted to ﬁnd
the optimal dosing regimen prior to allogeneic stem cell
transplantation.431
Vitamin D Supplementation Decreases Grade 3-4 Acute
GVHD in Allogeneic Transplants with Normal Baseline
Levels
David Frame 1,2, Robyn Beechuk 3, Denise Markstrom 4,
John Magenau 5, Daniel R. Couriel 5. 1 University of Michigan;
2 Blood and Marrow Transplant Program, University of
Michigan, Ann Arbor, MI; 3 Nutrition Services, Univeristy of
Michigan, Ann Arbor, MI; 4 Pharmacy, University of Michigan,
Ann Arbor, MI; 5 Adult Blood and Marrow Transplant Program,
University of Michigan
Background: Previous studies have shown that patients
receiving AHSCT are likely to have sub-optimal Vit D levels.
Vit D has also been shown to have signiﬁcant immuno-
modulatory effects, including polarization of T cell pop-
ulation towards Th2 expression and decreasing allogeneic
T-cell proliferation while increasing T-reg cell function.
Alloreactive T cells upregulate the Vit D receptor and reple-
tion of Vit D in vitro signiﬁcantly reduces this response. Thus
it is hypothesized that patients with VIT D deﬁciency at onset
of AHSCTwould have greater incidence and severity of GVHD
and that early replacement may lessen the risk of GVHD. In
this study we examine this relationship.
Methods: A retrospective evaluation of 290 adult AHSCT at
the University of Michigan between January 2007-December
2010. All patients had Serum 25-hydorxyvitamin D (25OHD)
levels at admission for AHSCT. Deﬁcient levels were deﬁned
to be below 29 ng/ml and normal levels as 30 ng/ml or
higher. The incidence and grade of GVHD were deﬁned as
maximum overall grade and acute GVHD was deﬁned as
starting within the ﬁrst 100 days. The primary standard
GVHD prophylaxis regimens were Tacrolimus/MTX for full
intensity and Tacrolimus /MMF for reduced intensity
transplants.
Results: Of all AHSCT 77% had Vit D deﬁciency at onset of
transplant with no difference between related donors (RD)
and unrelated donors (UD). Vit D supplementation was
started within the ﬁrst week of transplant and occurred in
83% who were Vit D deﬁcient at baseline and 36% of those
having normal levels at baseline. In patients with baseline Vit
D deﬁciency there did not appear to be an impact of Vit D
supplementation on the incidence of Grade 2-4 GVHD (44%
vs 46%) or Grade 3-4 GVHD (17% vs 19%). However in patients
who had baseline Vit D levels of 30 ng/ml or above there was
a signiﬁcant decrease in the incidence of Grade 3-4 GVHD in
the group who received Vit D supplementation versus those
who did not (9% vs 27%, X2¼2.99,P ¼ .042) and a trend
towards a decrease in Grade 2-4 GVHD (35% vs 54%,
X2¼2.11,P ¼ .073). This is despite having more Unrelated
Donor transplants in the Vit D supplemented group (65% vs
46%).Conclusion: AHSCT patients have high rates of Vit D deﬁ-
ciency. Ironically this study suggests that Vit D supplemen-
tation starting during transplant may signiﬁcantly decrease
the incidence of Grade 3-4 GVHD in patients who have
baseline levels >30 ng/ml but not those severely deﬁcient at
baseline. This could imply that higher amounts of Vit D
supplementation may be required to adequately effect T cell
response. Future trials should evaluate the role of increasing
Vit D supplementation and determine if an optimal Vit D
level is required to decrease the incidence and severity of
acute GVHD.432
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Chronic graft-versus-host disease (cGVHD) remains a major
cause of late phase mortality and morbidity after allogeneic
hematopoietic stem cell transplantation.We investigated the
roles of the PD-1 pathway in cGVHD using a well-deﬁned
mouse model (B10.D2 into BALB/c). First, we conﬁrmed that
CD4 and CD8 cells from the spleen and peripheral lymph
nodes (PLN) of allogeneic recipients expressed signiﬁcantly
more PD-1 compared to those of syngeneic recipients on
days 14, 21, 28, and 56 after transplantation (p < 0.05). Upon
transferring PD-1 KO donor T cells of the B10.D2 background
into allogeneic bone marrow transplantation (BMT) models,
there was severe weight loss and 100% of the recipients died
by day 23. To avoid early death and to examine the roles of
the PD-1 pathway in cGVHD, we next administered six
antibody doses to recipients of wild-type (WT) donors from
day 14 of BMT, just prior to the development of cGVHD. Mice
treated with anti-PD-1 showed 70% mortality by day 35 in
contrast to only 10% mortality in those administered anti-
B7H1 Ab or anti-B7DC Ab. All groups treated with anti-PD-1
Ab, anti-B7H1 Ab, or anti-B7DC Ab had signiﬁcantly higher
cGVHD scores than controls (anti-PD-1 Ab: 2.510.31, anti-
B7H1 Ab: 2.310.15, anti-B7DC Ab: 2.010.42, vs. control:
1.180.27, P < .05). To further examine the roles of the PD-1
pathway in cGVHD, we next used B7H1 KO mice as recipi-
ents. Allogeneic B7H1 KO BMT recipients showed signiﬁ-
cantly more severe skin cGVHD than WT controls (p < 0.05).
Histopathological examination of the skin showed signiﬁ-
cantly increased cGVHD damage in recipients of B7H1 KO
donors (5.86  0.85 vs. 8.38  0.38, P < 0.05). Since B7H1
expression of hematopoietic cells is critical for donor Treg
cell expansion, we then harvested cells from PLNs 14 and 28
days after BMT and analyzed cytokine expression levels.
Recipients of B7H1 KO showed fewer Foxp3+ regulatory T
cells in the early phase (day 14), whereas there was no
difference in the frequency of Foxp3+ regulatory T cells in the
late phase (day 28). We previously reported that Th1 and
Th17 cells contribute to the pathogenesis of cGVHD using this
mouse model. On day 28, IL-17+ IFNg+ T cells were detected
signiﬁcantly more frequently in recipients of B7H1 KO
donors than those of WT recipients (p < 0.05). These results
suggested that B7H1 expression in the recipient regulates
the frequency of IL-17+ IFNg+ T cells and Foxp3+ regulatory T
cells. Finally, we established chimeras that expressed B7H1
in hematopoietic cells, but not in parenchymal tissue by
transferring WT BM cells into B7H1KO recipients. Chimeric
